SG11201906968YA - Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease - Google Patents
Prophylactic and/or therapeutic agent of infectious disease or inflammatory diseaseInfo
- Publication number
- SG11201906968YA SG11201906968YA SG11201906968YA SG11201906968YA SG11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- prophylactic
- therapeutic agent
- inflammatory disease
- infectious disease
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 4
- 208000027866 inflammatory disease Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 230000000069 prophylactic effect Effects 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 102000009081 Apolipoprotein A-II Human genes 0.000 abstract 2
- 108010087614 Apolipoprotein A-II Proteins 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Environmental Sciences (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
Abstract
PROPHYLACTIC AND/OR THERAPEUTIC AGENT OF INFECTIOUS DISEASE OR INFLAMMATORY DISEASE [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein A2 (APOA2) as an active ingredient is provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017013486 | 2017-01-27 | ||
PCT/JP2018/002576 WO2018139608A1 (en) | 2017-01-27 | 2018-01-26 | Preventive and/or therapeutic agent for infectious diseases or inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906968YA true SG11201906968YA (en) | 2019-08-27 |
Family
ID=62978497
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906968YA SG11201906968YA (en) | 2017-01-27 | 2018-01-26 | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease |
SG10202108219QA SG10202108219QA (en) | 2017-01-27 | 2018-01-26 | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108219QA SG10202108219QA (en) | 2017-01-27 | 2018-01-26 | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease |
Country Status (9)
Country | Link |
---|---|
US (2) | US20190367600A1 (en) |
EP (2) | EP4317431A3 (en) |
JP (1) | JP7126658B2 (en) |
KR (1) | KR102581165B1 (en) |
CN (1) | CN110267680B (en) |
AU (1) | AU2018213716A1 (en) |
CA (1) | CA3051826A1 (en) |
SG (2) | SG11201906968YA (en) |
WO (1) | WO2018139608A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021085252A1 (en) * | 2019-10-30 | 2021-05-06 | 国立大学法人 岡山大学 | Prophylactic and/or therapeutic agent for inflammatory pulmonary disease |
WO2024004580A1 (en) * | 2022-06-30 | 2024-01-04 | 国立大学法人千葉大学 | Method for testing disease progression toward vasculitis or testing risk of covid-19 becoming severe, testing kit, companion diagnostic agent, and testing marker |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US164290A (en) | 1875-06-08 | Improvement in bedsteads | ||
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
JP2000014383A (en) | 1998-07-03 | 2000-01-18 | Igaku Seibutsugaku Kenkyusho:Kk | Humanized antibody |
FR2801407B1 (en) | 1999-11-22 | 2002-04-12 | Roger Felix Sejalon | CONTINUOUSLY TRACABLE INVIOLABLE LABEL BRACELET |
JP2004081199A (en) | 2002-06-25 | 2004-03-18 | Sekisui Chem Co Ltd | Method for producing recombinant antibody |
US9028822B2 (en) * | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
JP3965147B2 (en) | 2003-11-04 | 2007-08-29 | ヤンマー株式会社 | Claw shaft attachment / detachment structure of rotary tiller |
ATE546734T1 (en) * | 2003-12-05 | 2012-03-15 | Cleveland Clinic Foundation | RISK MARKERS FOR CARDIOVASCULAR DISEASE |
GB0701626D0 (en) * | 2007-01-22 | 2007-03-07 | Cambridge Entpr Ltd | Methods and biomarkers for diagnosing and monitoring psychotic disorders |
AU2008229385A1 (en) * | 2007-03-19 | 2008-09-25 | Sirtris Pharmaceuticals, Inc. | Biomarkers of sirtuin activity and methods of use thereof |
WO2009044723A1 (en) * | 2007-10-04 | 2009-04-09 | Biomarker Science Co., Ltd. | Method for prediction of effect of interferon therapy and kit for prediction |
GB0720976D0 (en) * | 2007-10-26 | 2007-12-05 | Medical Res Council | Treatment of inflammatory disease |
US8225183B2 (en) | 2008-09-30 | 2012-07-17 | Lsi Corporation | Methods and apparatus for selective data retention decoding in a hard disk drive |
US9435813B2 (en) * | 2010-05-11 | 2016-09-06 | The General Hospital Corporation | Biomarkers of hemorrhagic shock |
JP5998318B2 (en) | 2010-09-22 | 2016-09-28 | 国立大学法人 千葉大学 | New vasculitis test method and test reagent |
US10196457B2 (en) * | 2011-12-19 | 2019-02-05 | National University Corporation Chiba University | Artificial immunoglobulin fragment composition |
US10208131B2 (en) * | 2011-12-19 | 2019-02-19 | National University Corporation Chiba University | Artificially produced polyclonal immunoglobulin preparation |
CN105637366B (en) * | 2013-10-01 | 2018-05-29 | 东丽株式会社 | Detection method, antibody and the pancreas lesion detection kit of pancreas tumour |
JP5685672B1 (en) | 2014-07-10 | 2015-03-18 | 株式会社山岡製作所 | Resin molding method |
EP3252474B1 (en) * | 2015-01-26 | 2020-10-21 | Toray Industries, Inc. | Method and kit for detecting biliary tract cancer |
JP6670129B2 (en) * | 2015-02-27 | 2020-03-18 | 国立大学法人千葉大学 | Artificial immunoglobulin fragment composition |
WO2016140210A1 (en) * | 2015-03-02 | 2016-09-09 | 東レ株式会社 | Pancreatic dysfunction detection method and detection kit |
US9895848B2 (en) | 2015-04-22 | 2018-02-20 | The Boeing Company | Systems and tooling for manufacturing composite parts and related methods |
JP6453199B2 (en) | 2015-10-16 | 2019-01-16 | 光洋機械工業株式会社 | Centerless grinding machine |
-
2018
- 2018-01-26 WO PCT/JP2018/002576 patent/WO2018139608A1/en active Search and Examination
- 2018-01-26 US US16/481,241 patent/US20190367600A1/en not_active Abandoned
- 2018-01-26 EP EP23201475.3A patent/EP4317431A3/en active Pending
- 2018-01-26 CN CN201880008834.3A patent/CN110267680B/en active Active
- 2018-01-26 CA CA3051826A patent/CA3051826A1/en active Pending
- 2018-01-26 EP EP18744092.0A patent/EP3581204A4/en not_active Withdrawn
- 2018-01-26 SG SG11201906968YA patent/SG11201906968YA/en unknown
- 2018-01-26 KR KR1020197024894A patent/KR102581165B1/en active IP Right Grant
- 2018-01-26 SG SG10202108219QA patent/SG10202108219QA/en unknown
- 2018-01-26 JP JP2018564666A patent/JP7126658B2/en active Active
- 2018-01-26 AU AU2018213716A patent/AU2018213716A1/en active Pending
-
2022
- 2022-03-21 US US17/655,687 patent/US20220213180A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190367600A1 (en) | 2019-12-05 |
EP3581204A4 (en) | 2020-12-16 |
EP4317431A3 (en) | 2024-05-22 |
SG10202108219QA (en) | 2021-08-30 |
JPWO2018139608A1 (en) | 2020-01-09 |
CN110267680A (en) | 2019-09-20 |
WO2018139608A1 (en) | 2018-08-02 |
KR102581165B1 (en) | 2023-09-21 |
US20220213180A1 (en) | 2022-07-07 |
CN110267680B (en) | 2023-12-19 |
CA3051826A1 (en) | 2018-08-02 |
AU2018213716A1 (en) | 2019-08-15 |
EP4317431A2 (en) | 2024-02-07 |
KR20190108152A (en) | 2019-09-23 |
EP3581204A1 (en) | 2019-12-18 |
JP7126658B2 (en) | 2022-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
CL2020001852A1 (en) | Processes for the preparation of s-ketamine or s-ketamine hydrochloride or products derived from it. (divisional request 201901066) | |
CY1123693T1 (en) | RNAI AGENTS, COMPOSITIONS AND METHODS OF USING THEREOF FOR THE THERAPEUTIC TREATMENT OF TRANSTHYRETIN (TTR)-RELATED DISEASES | |
MX2023015185A (en) | Protein degraders and uses thereof. | |
EA201991862A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
EA201890736A1 (en) | Modulators of the cow protein of the hepatitis B virus | |
CY1122265T1 (en) | ANTIBODIES AGAINST THEM AND THEIR USES | |
EA201890394A1 (en) | COMPOSITIONS ON THE BASIS OF IRNA FOR TRANSTYRETINE (TTR) AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OR PREVENTION OF TTR ASSOCIATED DISTRIBUTIONS | |
MX2018003470A (en) | Novel anti-mesothelin antibody and composition comprising the same. | |
MX2022015250A (en) | Methods of treating inflammatory diseases. | |
EA201390156A1 (en) | PRODUCTION OF INTER-ALPHA INHIBITOR PROTEINS (IaIp) FROM PLASMA | |
MX2022006573A (en) | Methods of treating inflammatory diseases. | |
NZ761619A (en) | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 | |
EA201890185A1 (en) | METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID | |
EA201300130A1 (en) | METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | |
MX2017009038A (en) | Lingo-1 antagonists and uses for treatment of demyelinating disorders. | |
EA202090401A1 (en) | ANTI-TIM-3 ANTIBODIES AND THEIR APPLICATION | |
EA201890340A1 (en) | MONOCLONAL ANTIBODY-INHIBITOR OF FACTOR XIIA | |
MX2018005154A (en) | Single domain antibodies directed against intracellular antigens. | |
SG11201906968YA (en) | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease | |
MX2017015279A (en) | Exosomes and their use as vaccine. | |
WO2020123330A3 (en) | Anti-alpha-synuclein antibodies and uses thereof | |
NZ729803A (en) | A method for the treatment of motor neuron diseases | |
MX2022006145A (en) | Trem2 antibodies and uses thereof. | |
MX2017013480A (en) | Pharmaceutical composition for treating and/or preventing cancer. |